ClinicalTrials.gg
RecruitingNCT07923045MR-146Updated Nov 16, 2026

A Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II Neurotrophic Keratopathy

A Phase 1/2 interventional study of MR-146 in Neurotrophic Keratopathy, sponsored by Viatris Inc.. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Viatris Inc. · Phase 1/2, Interventional, and Treatment

Updated Nov 16, 2026Site recruiting status changedPrimary outcomes revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the safety, tolerability, and biologically effective dose (BED) of MR-146 for the treatment of Stage 1 and Stage 2 Neurotrophic Keratopathy (NK)

02

Conditions studied

  • Neurotrophic Keratopathy

Keywords

  • NK
  • neurotrophic keratopathy
  • neurotrophic keratitis
03

In context

Lead sponsor

Viatris Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be ≥18 years or greater of age at Visit 1.
  2. Have a diagnosis of Stage 1 or Stage 2 in the study eye for Part 1 or Stage 2 NK in the study eye for Part 2.
  3. Willing and able to participate in and attend to all study visits over the course of 12-14 months

Exclusion criteria

Exclusion Criteria:

  1. Have Stage 2 NK affecting both eyes, or Stage 3 NK in either eye.
  2. Any active ocular infections or active ocular inflammation not related to NK in the affected eye.
  3. Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study
  4. Have monocular vision in the study eye or have BSCVA less than 20/100 in the fellow eye.
  5. Any neurodegenerative disease (example: Parkinson's, Alzheimer's, Multiple Sclerosis, etc)
  6. Uncontrolled glaucoma in either eye.
  7. Any plan to use therapeutic contact lenses.
  8. Anyone pregnant, nursing, or planning to become pregnant within 3 months of participating in the study.
  9. History of incisional conjunctival surgery in the study eye.
  10. History of any ocular surgery in the affected eye within the last 3 months
  11. Botox use in the face or orbital area and/or lacrimal gland within the last 6 months.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    MR-146 (Low)

    Participants will receive a single low dose of MR-146 administered via an intralacrimal gland injection

    Genetic: MR-146

  • Experimental
    MR-146 (mid)

    participants will receive a single mid-level dose of MR-146 administered via an intralacrimal gland injection

    Genetic: MR-146

  • Experimental
    MR-146 (high)

    participants will receive a single high dose of MR-146 administered via an intralacrimal gland injection

    Genetic: MR-146

Interventions

  • GeneticMR-146

    gene therapy product for the treatment of stage I/II NK.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (Safety)

    To evaluate the safety of MR-146 through the incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: Week 52

  2. Incidence of serious adverse events (Safety)

    To evaluate the safety of MR-146 through the incidence of serious adverse events.

    Time frame: Week 52

  3. Incidence of adverse events (Safety)

    To evaluate the safety of MR-146 through the incidence of adverse events.

    Time frame: Week 52

07

Study locations

11 of 12 sites recruiting
  • Horizon Eye/DocTrials
    Sun City, Arizona 85351, United States
    Recruiting
    • Cason · Contact
  • Nvision
    Tucson, Arizona 85712, United States
    Recruiting
    • Villavicencio · Contact
  • Global Research Management
    Glendale, California 91204, United States
    Recruiting
    • El-Harazi · Contact
  • Loma Linda University Eye Institute
    Loma Linda, California 92354, United States
    Recruiting
    • Affeldt · Contact
  • NVision
    San Diego, California 92117, United States
    Recruiting
    • Pillar · Contact
  • Vision Institute
    Colorado Springs, Colorado 80907, United States
    Recruiting
    • Simmons · Contact
  • NewGen Health Research Group
    Miami, Florida 33176, United States
    Not yet recruiting
  • Butchertown Clinical Trials
    Louisville, Kentucky 40206, United States
    Recruiting
    • Pattar · Contact
  • 3RP (Red River Research Partners)
    Fargo, North Dakota 58103, United States
    Recruiting
    • Keating · Contact
  • EyeHealth Northwest
    Portland, Oregon 97225, United States
    Recruiting
    • Holland · Contact
  • Stuart A. Terry Eye Associates
    San Antonio, Texas 78212, United States
    Recruiting
    • Alsheikh · Contact
  • Virginia Eye Consultants
    Norfolk, Virginia 23502, United States
    Recruiting
    • Sheppard · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 6, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Global Research Management is now Recruiting
Show site
  • NewGen Health Research Group · Miami, United States
Nov 16, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • ChangedBefore SafetyNow Incidence of Dose-Limiting Toxicities (Safety)Time frame: Week 52
  • ChangedBefore SafetyNow Incidence of serious adverse events (Safety)Time frame: Week 52
  • ChangedBefore SafetyNow Incidence of adverse events (Safety)Time frame: Week 52
Nov 16, 2026
Title
A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in ParticipantsSubjects With Stage 1 or 2I and Stage II Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy
Nov 16, 2026
Registered
First appeared on the registry
Nov 6, 2026
Show all 2 updates
  1. Nov 16, 2026
    1 site added. Global Research Management is now Recruiting
    Show site
    • NewGen Health Research Group · Miami, United States
    Primary outcomes 3 edited
    What changed in the outcomes
    • ChangedBefore SafetyNow Incidence of Dose-Limiting Toxicities (Safety)Time frame: Week 52
    • ChangedBefore SafetyNow Incidence of serious adverse events (Safety)Time frame: Week 52
    • ChangedBefore SafetyNow Incidence of adverse events (Safety)Time frame: Week 52
    Title A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in ParticipantsSubjects With Stage 1 or 2I and Stage II Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy
    + 1 other change: design details
  2. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07923045
Lead sponsor
Viatris Inc.
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Jason Dierkhising
Contact
patientrecruitment@oraclinical.com
1707-484-1365

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion